Important note: The content on this page is educational only. Sacred Wellness does not facilitate or recommend illegal substance use. All information is intended to support informed conversations with your healthcare provider.
A turning point in mental health care
In 2026, the FDA announced national priority vouchers for three psychedelic compounds — marking the first time the agency has offered fast-track review to any psychedelic. The FDA is also clearing the way for first-ever U.S. human trials of ibogaine, a compound with remarkable potential for addiction and PTSD.
This is not fringe science. This is the mainstream medical establishment responding to decades of rigorous research showing that these compounds, administered in therapeutic settings, can produce profound and lasting healing — often in just a few sessions.
For many people — especially those with treatment-resistant depression, PTSD, addiction, or trauma — this research represents real hope. Sacred Wellness is here to help you understand it clearly.
How Psychedelics Work
These compounds temporarily disrupt default mode network activity in the brain, creating a window of neuroplasticity — making entrenched patterns more accessible to change.
Set, Setting & Support
Research consistently shows that outcomes depend heavily on preparation, intention, the therapeutic environment, and post-session integration — not just the substance itself.
What We Track
We follow FDA proceedings, peer-reviewed publications, clinical trial results, and legal developments to keep our education current and accurate.
What the studies show
Psilocybin & Depression
Studies at Johns Hopkins found that two psilocybin sessions, combined with therapy, produced rapid and lasting reductions in major depressive disorder — with effects lasting over a year for many participants.
MDMA-Assisted Therapy for PTSD
Multi-site Phase 3 trials showed 67-71% of participants no longer met PTSD criteria after three MDMA-assisted therapy sessions, compared to 32% in the placebo group.
Ibogaine & Addiction
Ibogaine has shown extraordinary promise for treatment-resistant addiction and PTSD, particularly among veterans. The FDA's 2026 move to enable first-ever U.S. human trials marks a historic turning point.
Ketamine for Treatment-Resistant Depression
Ketamine-based treatment (Spravato) is now FDA-approved for treatment-resistant depression — the first fast-acting antidepressant in decades, and a legal gateway into psychedelic-adjacent care.
Our Commitments
- Sacred Wellness does not administer, prescribe, or facilitate the use of any controlled substances.
- All educational content is for informational purposes only and does not constitute medical advice.
- Always consult a qualified healthcare professional before making decisions about your mental health care.
- Psychedelic-assisted therapy is currently legal only within FDA-approved clinical trial settings in the U.S.
Have questions about your options?
Book an educational consultation. We'll help you understand the landscape clearly — with zero judgment and zero pressure.
Book a Free Education Consultation